Previous close | 1.3200 |
Open | 1.3500 |
Bid | 1.3000 x 1000 |
Ask | 1.3500 x 2900 |
Day's range | 1.2903 - 1.3500 |
52-week range | 0.6800 - 4.9400 |
Volume | |
Avg. volume | 29,125 |
Market cap | 35.341M |
Beta (5Y monthly) | -1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.1970 |
Earnings date | 28 Mar 2023 - 03 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.51 |
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD)The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for patientsHaving recently reached a significant milestone of testing over 12,500 participants, the study now aims to recruit and genetic
Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq: CNTG], the essential life science partner for data-driven answers in rare and neurodegenerative diseases, have announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby inc